Orion Pharma’s ODM-212 Granted Orphan Designation for the Treatment of Malignant Mesothelioma by the European Commission

Orion Pharma's ODM-212 Receives EU Orphan Designation for Mesothelioma

Orion Pharma's investigational drug, ODM-212, has received Orphan Designation from the European Commission for the treatment of malignant mesothelioma, a rare and difficult-to-treat cancer. This follows a previous Orphan Drug Designation from the US FDA for mesothelioma. ODM-212, an oral small-molecule pan-TEAD inhibitor, is currently in a global Phase 2 clinical study (TEADES) for malignant pleural mesothelioma, epithelioid hemangioendothelioma, and other solid tumors with Hippo pathway dysfunction, specifically for patients who have progressed after standard treatments. The EU designation provides Orion Pharma with incentives such as protocol assistance, fee reductions, and eligibility for 10 years of market exclusivity post-approval.

• The European Commission's Orphan Designation for ODM-212 was based on the recommendation from the European Medicines Agency’s (EMA) Committee for Orphan Medicinal Products (COMP). This designation is granted to medicines for life-threatening or chronically debilitating rare diseases, defined by a prevalence of no more than 5 in 10,000 in the EU, and where there is no satisfactory treatment or the medicine offers significant benefit.
• With this Orphan Designation, Orion Pharma, as the sponsor, is now qualified for several incentives. These include protocol assistance, fee reductions for certain regulatory activities, and eligibility for a 10-year period of market exclusivity following approval. It is important to note that this designation does not shorten the development time or regulatory review process of the drug.
• ODM-212 is an oral small-molecule pan-TEAD (Transcriptional Enhanced Associate Domain) inhibitor developed by Orion Pharma. It targets the Hippo signaling pathway, which regulates cell growth. The drug works by blocking TEAD transcription factors, disrupting YAP-TEAD protein-protein interactions, and inhibiting TEAD auto-palmitoylation, which is essential for TEAD activity, thereby addressing dysregulation that can lead to tumor growth.

Addressing Critical Unmet Needs in Malignant Mesothelioma

Malignant pleural mesothelioma (MPM) remains a highly lethal malignancy with a critically limited systemic treatment landscape. Despite incremental advances across surgery, radiotherapy, and chemotherapy, survival outcomes remain poor and the disease continues to carry a high case fatality rate.

• Scarcity of effective systemic treatment options: MPM has few approved systemic therapies, and existing modalities — including surgery, radiotherapy, and chemotherapy — have failed to meaningfully improve long-term survival rates, underscoring a persistent and significant unmet clinical need.

• Adverse impact of post-diagnosis air pollution exposure on survival: Emerging evidence indicates that environmental exposures compound poor outcomes in asbestos-related cancers. The 1-, 3-, and 5-year survival rates for both MPM and asbestos-related lung cancer decreased with increasing exposure to air pollutants, with a quartile increase in the pollutant mixture associated with a 1.99-fold increase in MPM-related mortality risk (95% CI: 1.62, 2.44). Limited research into these exposures has historically been constrained by the disease's high case fatality rate.

• Lack of validated prognostic and diagnostic biomarkers: Identifying reliable biomarkers to guide treatment stratification remains a challenge. COL1A1 and COL1A2 gene expression have demonstrated diagnostic potential (AUC: 0.900 and 0.897, respectively) and prognostic relevance, with high expression and biphasic histology correlating with increased mortality risk (Cox multivariate analysis, P<0.05), yet these markers are not yet integrated into routine clinical decision-making.

• Inadequate targeting of key oncogenic drivers: c-Src, a non-receptor tyrosine kinase implicated in proliferation, invasion, motility, survival, and angiogenesis, is highly expressed and activated in MPM tumor specimens. While c-Src inhibition via dasatinib has shown preclinical promise — inducing cell cycle arrest, apoptosis, and inhibition of migration independent of cytotoxic effects — activated Src expression (p-Src Y419) correlates with advanced-stage disease and metastasis, highlighting an oncogenic axis that remains inadequately addressed by current standard-of-care regimens.

Navigating the Malignant Mesothelioma Treatment Landscape

The available literature highlights several therapeutic modalities employed in malignant mesothelioma (MM), though the evidence base reflects an evolving rather than fully standardized treatment paradigm. Immunotherapy has emerged as a prominent approach, yet its clinical benefit remains limited — fewer than 40% of patients demonstrate meaningful responses. Research has begun to characterize predictive biomarkers that may explain this variability, with genomic alterations in TP53, CDKN2A, or CDKN2B associated with diminished immunotherapy efficacy. Concurrently, T-cell receptor (TCR) repertoire characteristics — specifically, lower clonotypic evenness (below 0.030) in baseline tumor tissue — have also been linked to poorer outcomes. Five distinct TCR Vβ-Jβ rearrangements have been identified as potentially associated with immunotherapy response, offering a foundation for prospective biomarker-driven trial design.

For peritoneal mesothelioma, cytoreductive surgery combined with heated intraperitoneal chemotherapy (CRS/HIPEC) represents an established surgical intervention. However, the benefit of this approach is contingent on achieving complete cytoreduction; incomplete cytoreduction (CCR2/3) is associated with significant morbidity without a corresponding survival advantage. Preoperative clinical factors predictive of incomplete cytoreduction include male sex (OR 3.4), presence of ascites (OR 2.8), CA-125 ≥40 U/mL (OR 3.4), and CEA ≥4.2 ng/mL (OR 3.2), underscoring the importance of careful patient selection prior to surgical intervention.

At the investigational level, targeted therapy against the non-receptor tyrosine kinase c-Src has been explored in malignant pleural mesothelioma (MPM). Dasatinib, a c-Src inhibitor, demonstrated cytotoxic activity in three of four MPM cell lines, inducing cell cycle arrest, increasing apoptosis, and inhibiting cellular migration and invasion independently of cytotoxic effects. Notably, elevated expression of activated c-Src (p-Src Y419) on tumor cell membranes correlated with advanced disease stage and the presence of metastasis, while lower membrane expression of inactive c-Src (p-Src Y530) was associated with advanced nodal stage — findings that collectively position c-Src inhibition as a potentially meaningful therapeutic strategy worthy of further clinical investigation.

Orphan Status Fuels Pan-TEAD Inhibitor's Broad Oncology Ambitions

Orion Pharma's recent European Orphan Designation for ODM-212 in malignant mesothelioma is a pivotal development, underscoring the growing focus on rare oncology indications with significant unmet needs. This follows a similar designation from the US FDA, collectively providing substantial regulatory support and commercial advantages, including a decade of market exclusivity in the EU. Such incentives are critical for de-risking the development of novel therapies for challenging diseases like mesothelioma, which often present with poor prognoses and limited treatment options.

ODM-212 operates as an oral small-molecule pan-TEAD inhibitor, targeting the transcriptional enhanced associated domain (TEAD) proteins. This mechanism is central to the Hippo pathway, a critical signaling cascade whose dysregulation, particularly through aberrant YAP/TAZ-TEAD activation, is a known driver in various cancers. The ongoing Phase 2 TEADES study is exploring ODM-212 not only in malignant pleural mesothelioma but also in epithelioid hemangioendothelioma and other solid tumors with Hippo pathway dysfunction, specifically for patients who have progressed after standard treatments. This broad scope is strategically important, as research indicates the YAP/TAZ-TEAD axis plays a crucial role in tumor growth in conditions like PI3K-activated sarcomas, suggesting potential for combination therapies, for instance, with mTORC1 inhibitors.

Beyond direct anti-tumor effects, studies also highlight the Hippo pathway's involvement in the tumor microenvironment, particularly in cancer-associated fibroblasts (CAFs), where its dysregulation can contribute to immunotherapy resistance. This opens a compelling avenue for ODM-212 to be explored in combination with immune checkpoint inhibitors, potentially improving outcomes for patients who are currently unresponsive. However, the path forward is not without its challenges. The literature points to potential on-target effects such as nephrotoxicity, which will require careful clinical management and potentially influence dosing strategies. Acquired resistance is another consideration for TEAD inhibitors, suggesting that long-term efficacy may necessitate combination approaches or intermittent dosing schedules. Furthermore, the TEAD inhibition space is an active area of research, implying that future differentiation will be key for ODM-212 to stand out in a potentially competitive landscape. Orion Pharma's strategic positioning with Orphan Designations provides a strong foundation, but navigating these clinical and competitive dynamics will be crucial for realizing the full therapeutic and commercial potential of ODM-212.